Scholars Central

Mini reviewPublished 27 Feb 2023

Targeting Changes in the RAF-MEK Pathway

Authors: Peter Koulen

Journal of Bioprocessing & Biotechniques

Volume 13 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

One of the most frequently mutated oncogenic pathways in cancer is the MAPK pathway. Although RAS mutations are the most common MAPK changes, changes in downstream components of the pathway, such as the RAF and MEK genes, offer promising therapeutic opportunities. Other alterations in the RAF and MEK genes may provide rarer, but tractable, targets in addition to BRAFV600 mutations, for which several approved therapeutic regimens, exist. Recent studies, however, have demonstrated the complexity of MAPK signalling and highlighted the fact that different alterations in these genes may have strikingly different properties. Understanding the distinct functional properties of specific RAF and MEK alterations, as discussed here, will be critical for developing effective therapeutic approaches for these targets.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioprocessing & Biotechniques.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioprocessing & Biotechniques
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Peter Koulen”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels